ESR2 and triple-negative breast carcinoma: Future research should focus on experimental validation of these compounds’ activity, particularly in ERβ-expressing cell lines, along with further pharmacodynamic and pharmacokinetic studies to elucidate their mechanism of action and in vivo efficacy, paving the way for new therapeutic strategies against triple-negative breast cancer.